Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift


Even with the availability of targeted drugs, allogeneic hematopoietic cell transplantation (allo-HCT) is the only therapy with curative potential for patients with CLL. Cure can be assessed by comparing long-term survival of patients to the matched general population. Using data from 2589 patients who received allo-HCT between 2000 and 2010, we used landmark analyses and methods from relative survival analysis to calculate excess mortality compared with an age-, sex- and calendar year-matched general population. Estimated event-free survival, overall survival and non-relapse mortality (NRM) 10 years after allo-HCT were 28% (95% confidence interval (CI), 25-31), 35% (95% CI, 32-38) and 40% (95% CI, 37-42), respectively. Patients who passed the 5-year landmark event-free survival (N=394) had a 79% probability (95% CI, 73-85) of surviving the subsequent 5 years without an event. Relapse and NRM contributed equally to treatment failure. Five-year mortality for 45- and 65-year-old reference patients who were event-free at the 5-year landmark was 8% and 47% compared with 3% and 14% in the matched general population, respectively. The prospect of long-term disease-free survival remains an argument to consider allo-HCT for young patients with high-risk CLL, and programs to understand and prevent late causes of failure for long-term survivors are warranted, especially for older patients.


  • Marion E Meijer-Van Gelder
  • L. C. De Wreede
  • M. Bornhäuser
  • D Niederwieser
  • M. Karas
  • N. S. Anderson
  • Martin Gramatzki
  • P. Dreger
  • Mauricette Michallet
  • Bo E Petersen
  • D. Bunjes
  • Michael N Potter
  • D. Beelen
  • Jan J Cornelissen
  • I. Yakoub-Agha
  • Nigel H Russell
  • J. Finke
  • H. Schoemans
  • A Vitek
  • Urbano-Ispízua
  • D. Blaise
  • L Volin
  • Patrice Chevallier
  • Dolores Caballero
  • H. Putter
  • Anja van Biezen
  • A. Henseler
  • S O Schönland
  • Nicolaus Kröger
  • J. Schetelig
  • Gerhard Ehninger
  • Dietger Niederwieser
  • Pavel Jindra
  • Henrik Sengeloev
  • Martin Gramatzki
  • Peter Dreger
  • Eefke Petersen
  • Donald Bunjes
  • Michael N Potter
  • Dietrich Beelen
  • Jan Cornelissen
  • Ibrahim Yakoub-Agha
  • Nigel Russell
  • Jürgen Finke
  • Hélène Schoemans
  • Antonin Vitek
  • Alvaro Urbano Ispizua
  • Didier Blaise
  • Stig Lenhoff
  • Carlos Solano
  • Chronic Malignancy Working Party
Enheter & grupper
Externa organisationer
  • DKMS gemeinnützige GmbH
  • Medizinsche Klinik und Poliklinik I, Dresden
  • University Hospital in Pilsen
  • Copenhagen University Hospital
  • University Medical Center Schleswig-Holstein Campus Kiel
  • Heidelberg University
  • University Medical Center Utrecht
  • University Hospital of Ulm
  • Royal Marsden Hospital
  • University Hospital Essen
  • Erasmus University Medical Center
  • Lille University Hospital
  • Nottingham City Hospital
  • Albert-Ludwigs University Freiburg
  • University Hospitals Leuven
  • Institute of Hematology and Blood Transfusion
  • Hospital Clínic of Barcelona
  • Institut Paoli-Calmettes
  • Skåne University Hospital
  • Yukioka Hospital
  • Leiden University Medical Centre
  • Centre Hospitalier Lyon Sud
  • Helsinki University Central Hospital
  • Nantes University Hospital
  • University Hospital of Salamanca
  • University Medical Center Hamburg-Eppendorf
  • University and Polytechnic Hospital la Fe
  • University Hospital Leipzig

Ämnesklassifikation (UKÄ) – OBLIGATORISK

  • Hematologi


Sidor (från-till)372-380
Antal sidor9
TidskriftBone Marrow Transplantation
StatusPublished - 2017 mar 1
Peer review utfördJa